MISSISSAUGA, Ontario, June 29, 2018 /CNW/ -- Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company") today announced the results of the matters voted upon at the Company's 2018 annual meeting (the "Meeting") of the shareholders of the Company (the "Shareholders") held earlier today, which included the election of directors, as described below.
The total number of common shares of the Company ("Common Shares") represented by Shareholders present in person or represented by proxy at the Meeting was an aggregate of 48,911,838, representing 72.79% of the Company's issued and outstanding Common Shares as of the record date for the Meeting.
According to proxies received and a vote by ballot, the voting results in respect of each of the following seven director nominees, all of whom previously served as directors of the Company, were as follows:
Number of Shares
Percentage of Votes Cast (approximate)
Arthur S. Kirsch (Chairperson)
Neal F. Fowler
Kenneth B. Lee, Jr.
Seth A. Rudnick, M.D.
F. Martin Thrasher
Each of the other matters bought before the Shareholders for consideration and approval at the Meeting, as described in the Company's proxy statement dated May 18, 2018, was duly approved by the requisite number of votes.
Final voting results of all other matters voted on at the Meeting will be made available on EDGAR at www.sec.gov and SEDAR at www.sedar.com.
About Aralez Pharmaceuticals Inc. Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) is a Canadian specialty pharmaceutical company focused on delivering meaningful products to improve patients' lives while creating shareholder value by acquiring, developing and commercializing products in various specialty areas. Aralez's Global Headquarters is in Mississauga, Ontario, Canada and the Irish Headquarters is in Dublin, Ireland. More information about Aralez can be found at www.aralez.com.